A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

NCT01332994 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

519

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: rituximab [MabThera/Rituxan]
DRUG: tocilizumab [RoActemra/Actemra]
DRUG: tocilizumab [RoActemra/Actemra]

Sponsor

Hoffmann-La Roche